Background: Few studies have evaluated risk factors for patterns of foot pain in the general population, let alone over time. An understanding of the possible predictors is the first step towards evidencebased interventions. The purpose of this study was to examine risk factors for the onset and persistent of severe foot pain in men and women of the population-based Framingham Foot Study (FFS). Methods: The longitudinal FFS included 648 participants who attended baseline (BL, 2002-5) and follow-up (FU, 2005-8) exams. The presence of foot pain at both BL and FU was queried using the question: On most days, do you have pain, aching, or stiffness in either of your feet? If participants had foot pain, severity was then queried as mild, moderate or severe. We dichotomized pain severity into 2 pain groups: moderate/severe vs none/mild for each foot. Two separate analyses were done to examine 1) onset of moderate/severe pain vs none/mild pain and 2) persistent severe/moderate pain vs resolving severe/moderate pain. Two per-foot analyses using logistic regression and generalized estimating equations were used to examine the association between onset vs no foot pain and persistent vs resolving foot pain with potential risk factors (age, sex, BMI, current smoking, knee pain, hip pain and low back pain). Models were also examined by sex. Results: At BL, in the 648 participants (1296 feet) average age was 65 years (range 36-86, S.D. ¼ 9), BMI was 29 kg/m 2 (S.D. ¼ 5), 51% were female and mean follow-up time was 3 years (range 1-6). 85% had no pain, 5% had onset, 7% had resolving, and 3% had persistent pain. Female sex (P ¼ 0.04) and current smoking (P ¼ 0.02) was associated with a 2-3 fold increased odds of onset of pain. Increased BMI (P ¼ 0.01) was associated with a 16-20 fold increased odds of persistent vs resolving pain (Table 1 ). In the sex-specific models, current smoking maintained its effect with onset pain, but was nonsignificant (OR men ¼ 3.4, P ¼ .07; OR women ¼ 2.4, P ¼ .11). The elevated odds of persistent pain remained for overweight (OR ¼ 14, P ¼ .20) and obese men (OR ¼ 7, P ¼ .10) but not for women. These non-significant results are not surprising given the small numbers in individual cells. Conclusion: A larger study with longer follow-up is needed to identify risk factors and patterns of foot pain over time. Looking at foot disorders, in addition to pain, is also of interest. Nevertheless, in our study current smoking regularly appears to be linked with onset of moderate to severe foot pain, which is in agreement with common clinical observations that smokers develop more foot problems than non-smokers. Additionally, increased BMI was suggestively linked to persistent moderate to severe foot pain compared with those whose pain resolved.
Disclosure statement: The authors have declared no conflicts of interest. There is a greater emphasis on achieving remission. We have used observational data from a single locality to ask two questions. First what has been the impact of these management changes on patients seen in specialist clinics? Second has changed continued over time or has is stalled? Methods: Our observational study included 1492 RA patients attending two adjacent rheumatology centres. They comprised four groups of consecutive clinic attenders with RA attending between 1996 and 2013. We collected demographic data (gender, age and disease duration), disease activity (DAS28 scores and the individual components) and the use of DMARDs and biologics. We compared cohorts using descriptive statistics and evaluated the frequencies of remission and active disease by calculating odds ratios (with 95% CI) and using the Mantel-Haenszel test to evaluate trends. Results: Gender frequencies, mean age and mean disease duration were similar in each patient group. Mean DAS28 scores fell from 5.1 in 1996-97 to 3.7 in 2009-2010; this was an annual fall of 0.1/year. The rate of change declined after 2010 and DAS28 scores stabilized at 3.5 in 2012-13. The proportion of patients in remission (DAS28 2.6) increased over time with the Mantel-Haenszel test showing a highly significant trend (P < 0.001); the most marked increase was between 2001-2003 and 2009-2010 , when rates rose from 9% to 23%. The frequency of active disease reduced over time with the MantelHaenszel test showing a highly significant trend (P < 0.001); again the most marked fall was between 2001-03 and 2009-10, when rates fell from 44% to 21%. Throughout the period the frequency of intermediate disease activity (DAS28 3.2-5.1) was static (37-42%) ( Table 1) . Conclusion: The disease activity of RA patients attending rheumatology clinics has changed dramatically over time. There has been a marked reduction in the frequency of active disease and an increase in remissions. Further improvement in achieving lower disease activity has now plateaued.
CHANGING PATTERNS IN RHEUMATOID ARTHRITIS DISEASE ACTIVITY
Current treatment pathways for RA were designed when many patients had active RA. This is particularly true for access to biologics. We suggest that additional management changes will be needed to further increase remission rates. Patients with intermediate disease activity RA now form the largest group of clinic attenders and we need to focus upon these patients.
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DOES TREATING EARLY RHEUMATOID ARTHRITIS

Background:
The BSRBR was established to compare the long term safety of anti-tumour necrosis factor drugs (TNFi) with non-biologic drugs (nbDMARDs) in subjects with RA. Serious adverse events (SAEs) are identified by clinician and patient reporting as well as linkage to the national death register. We used myocardial infarction (MI) as an example to explore whether differential under-reporting of SAEs to BSRBR exists between treatment groups by linking BSRBR to the Myocardial Ischaemia National Audit Project (MINAP), a registry of all hospitalizations with MI in England and Wales (E&W). Methods: This analysis was limited to subjects living in E&W. BSRBR and MINAP were linked using deterministic matching with combinations of first and last names, birthdate, postcode, National Health Service number, sex. Events from both datasets were matched by subject using a 30-day window. Matched and unmatched events were verified using the American Heart Association/European Society of Cardiology criteria for MI. Deaths from MI (reported as the underlying cause of death using ICD-10 via death register linkage) were also included as verified MIs. Age, sex, treatment group, MI phenotype, whether subjects received cardiology care at the same hospital as rheumatology care, location of MI deaths were explored as possible reasons for non-overlap between datasets using descriptive statistics. The risk of MI was compared between subjects receiving nbDMARDs and ever-exposed to TNFi using a Cox regression model, adjusted for deciles of propensity scores (PD) (Table 1) using (i) MIs verified from BSRBR-only, (ii) all MIs verified from BSRBR or MINAP. Subjects were censored at first MI, death, last clinician follow-up or 20/4/2010, whichever came first. Results: In total, 310 verified MIs were recorded during the observation period: 75% were captured in BSRBR, 64% captured in MINAP and 39% captured in both ( (2008) recommend that future research should address multisite joint pain as it is more severe and disabling than single site joint pain. The aim of this study was to describe the prevalence and risk of self-reported consultation with a General Practitioner (GP) or Practice Nurse (PN) for single site and multisite peripheral joint pain. Methods: A cross-sectional population survey was mailed to adults aged 45 years and over (n ¼ 28 443) registered with 8 general practices in the North West Midlands as part of the MOSAICS study. Participants provided information on the presence of joint pain in the hands, hips, knees and feet and recorded whether they had consulted a GP or PN for their joint pain in the last 12 months. Consultations for either single site or multisite joint pain (pain in two or more sites) were noted. The relative risk (RR) and attributable risk (AR) of consulting a 38 
